<DOC>
	<DOCNO>NCT00002403</DOCNO>
	<brief_summary>The purpose study see safe effective give zintevir ( AR177 ) asymptomatic ( symptom ) HIV-infected patient . Zintevir belong new class anti-HIV drug , integrase inhibitor . HIV use protein integrase infect cell . Integrase inhibitor block integrase may stop replication HIV .</brief_summary>
	<brief_title>Safety Effectiveness Zintevir ( AR177 ) Given HIV-Infected Patients</brief_title>
	<detailed_description>Zintevir belong new class anti-HIV drug , integrase inhibitor . The HIV-1 virus use protein integrase incorporate genetic material infect host cell . Integrase inhibitor block integrase may stop replication HIV-1 virus . In open-label , Phase I/II study , 3 group HIV-positive patient ( 12 patient total ) receive escalate dos intravenous zintevir 14 consecutive day .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are HIVpositive , symptom HIV infection . Have CD4 count great 200 cells/mm3 . Have viral load ( level HIV body ) great 4,000 copies/ml . Are least 18 year old . Exclusion Criteria You eligible study : Tend abnormal bleed blood problem . Have active AIDSdefining illness . Have history serious disease illness . Abuse alcohol drug . Have receive certain medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 1999</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>HIV Integrase Inhibitors</keyword>
	<keyword>HIV Integrase</keyword>
</DOC>